Retrospective analysis of the etiology and drugs for vitreous hemorrhage caused by non-diabetic retinopathy and non-traumatic factors.

OBJECTIVE

To retrospectively analyze the etiology of non-diabetic retinopathy (DR) and non-traumatic vitreous haemorrhage (VH), and the effects of different anti-vascular endothelial growth factor (VEGF) drugs.

METHODS

A retrospective analysis was conducted on VH patients diagnosed as non-diabetic retinopathy or trauma. Among 101 patients treated with anti-VEGF drugs, there were 48 cases in the Conbercept group and 53 cases in the Ranibizumab group. The causes of bleeding and gender distribution of the included cases were analyzed.

RESULTS

In cases of retinal vein occlusion, the proportion of males was much higher than females (p < 0.05). After treatment, the best corrected visual acuity (BCVA), intraocular pressure, central macular thickness (CMT), aqueous humor VEGF, TNF-α, IL-10, and IL-6 of the two groups showed a decreasing trend (p < 0.05). The Conbercept group had markedly lower CMT than the Ranibizumab group (p < 0.05). In addition, there existed no significant statistical differences between the two groups in terms of BCVA, intraocular pressure, aqueous humor VEGF, TNF-α, IL-10, IL-6, incidence of adverse reactions, and recurrence rate (p > 0.05).

CONCLUSION

In patients with non-DR and traumatic VH, retinal vein occlusion, perivenous retinitis, retinal tears/detachment, exudative AMD, and polypoidal choroidal vasculopathy were the main etiologies. Conbercept and Ranibizumab had comparable efficacy and could effectively improve visual acuity and aqueous humor inflammation, with high safety and low recurrence rate. Conbercept had a more pronounced effect on the reduction of CMT in patients.